TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30785496
Drug: Oregano essential
Normalized name: Oregano
DrugBank: Oregano (DB10677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregano essential oil (OEO) at 150 mg.kg‐1
Study: 30785496
Drug: Oregano essential
Normalized name: Oregano
DrugBank: Oregano (DB10677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregano essential oil (OEO) at 200 mg.kg‐1
Study: 30785496
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (CT) with zinc bacitracin
Study: 26605836
Drug: Ranibizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.3 mg)
Study: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg
Study: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 400 mg
Study: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg (2 doses)
Study: 25731901
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 400 mg (2 doses)
Study: 22950861
Drug: Topiramate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (10 mg/kg once a day for the first 3 days of life) with moderate hypothermia
Study: 22950861
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with moderate hypothermia alone
Study: 21058473
Drug: G‐CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF plus acupuncture (A)
Study: 16306522
Drug: Timolol (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (nonselective beta-blocker)
Study: 10096387
Drug: Finasteride treatment
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride treatment for 24 to 30 months
Study: 2291868
Drug: Captopril (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5, 25 and 50 mg)
Study: 42628
Drug: Oxazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (15 mg)
Study: 7316551
Drug: Topical exothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical exothermic pads (hyperthermia)
Study: 28875371
Drug: Heparin group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin group (heparin bolus 70 IU per kg body weight before PA catheter insertion)
Study: 19909743
Drug: 5% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% mannitol meal (350 mL)
Study: 19909743
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose meal (350 mL)
Study: 17983937
Drug: Insulin sensitizers
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin sensitizers
Study: 15636619
Drug: Preemptive standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive standard (IFN) or pegylated (peg-IFN) interferon alfa-2b (3 MU thrice weekly or 1.5 microg/kg weekly) plus ribavirin (600 mg increased to 1.0-1.2 g daily) initiated 2-6 weeks post-transplantation for 48 weeks
Study: 15636619
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFN/peg-IFN plus ribavirin)
Study: 17889491
Drug: Oral gemifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gemifloxacin
Study: 12132563
Drug: Oral clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clarithromycin
Study: 10212514
Drug: Artesunate (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (700 mg oral for 5 days)
Study: 7790130
Drug: Perceived peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived peer norms regarding drug-related risk reduction
Study: 2127095
Drug: Cooperative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooperative Care (CC) program
Study: 7005645
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (cyclophosphamide 200 mg/m2 IV weekly x 4 and Adriamycin 40 mg/m2 IV weeks 1 and 3)
Study: 7005645
Drug: No intensive
Normalized name: TITANIUM DIOXIDE 11.4072 g in 100 g TOPICAL POWDER [BUENO INTENSIVE FITTING CUSHION FOUNDATION SPF 50 PA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intensive treatment (control group)
Study: 12107604
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonists
Study: 19132857
Drug: CSII with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII with RT-CGM as an adjunct to SMBG (n = 14)
Study: 19132857
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) and self-monitoring of blood glucose (SMBG) (control arm)
Study: 16508637
Drug: FOLFOXIRI (CPT‐11
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI (CPT‐11 150 mg m(‐2) on d1, L‐OHP 65 mg m(‐2) on d2, LV 200 mg m(‐2) on days 2 and 3, 5‐FU 400 mg m(‐2) as i.v. bolus and 600 mg m(‐2) as 22 h i.v. continuous infusion on days 2 and 3, every 2 weeks)
Study: 16508637
Drug: FOLFIRI (CPT‐11
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (CPT‐11 180 mg m(‐2) on d1, LV and 5‐FU administered as in FOLFOXIRI, every 2 weeks)
Study: 28439987
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg/day
Study: 28634217
Drug: Participants taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Study: 28634217
Drug: Participants not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants not taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Study: 21350366
Drug: Engerix B,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix B, 20 μg HBsAg
Study: 21350366
Drug: Engerix B,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix B, 40 μg
Study: 21350366
Drug: Twinrix, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix, 20 μg HBsAg combined with 720 ELU hepatitis A antigen
Study: 9765723
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus supportive care
Study: 9765723
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens containing cisplatin
Study: 30542740
Drug: Chemotherapy (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (not specified)
Study: 9765723
Drug: Chemotherapy using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy using long-term alkylating agents other than cisplatin
Study: 3740675
Drug: Chemotherapy (general)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (general)
Study: 3691624
Drug: Amodiaquine 200
Normalized name: amodiaquine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine 200 mg
Study: 3691624
Drug: Amodiaquine 400
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine 400 mg
Study: 3691624
Drug: Amodiaquine 600
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine 600 mg
Study: 3691624
Drug: Amodiaquine 200
Normalized name: amodiaquine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine 200 mg, 400 mg, 600 mg
Study: 23664208
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ranibizumab and PDT
Study: 18158000
Drug: Training and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training and Support Program (TSP); 8 weekly sessions, 1 hour each, taught by qualified therapists.
Study: 16259645
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d nemifitide
Study: 16259645
Drug: 45 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/d nemifitide
Study: 10674778
Drug: Respiratory syncytial
Normalized name: Respiratory syncytial virus Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory syncytial virus immune globulin intravenous (RSV‐IGIV)
Study: 1280735
Drug: SCH 34826
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 34826 (400 mg every 6 hours for five doses)
Study: 23259260
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture therapy combined with conventional rehabilitation training
Study: 21082868
Drug: Anacetrapib 100
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 100 mg daily for 18 months
Study: 16190570
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with pegylated interferon
Study: 16190570
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of consensus interferon and ribavirin
Study: 11431944
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg tranexamic acid before skin incision and after the start of cardiopulmonary bypass
Study: 11431944
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg tranexamic acid
Study: 22840421
Drug: Lutein plus
Normalized name: Lutein Plus with Zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein plus zeaxanthin (L+Z) 10 mg/2 mg; n = 1044
Study: 22840421
Drug: ω‐3 long‐chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 long‐chain polyunsaturated fatty acids (LCPUFA) (eicosapentaenoic acid + docosahexaenoic acid [650 mg/350 mg]; n = 1069)
Study: 22840421
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L+Z and ω‐3 LCPUFAs; n = 1078
Study: 22840421
Drug: Original AREDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original AREDS formulation with variations in zinc and β‐carotene
Study: 20723301
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus dipyridamole (100 mg/day)
Study: 29630101
Drug: Simple chemotherapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple chemotherapy
Study: 15877873
Drug: Carbonated mineral
Normalized name: Mineral carbon
DrugBank: Graphite (DB18717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbonated mineral water (1 litre daily for 8 weeks)
Study: 15877873
Drug: Control mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control mineral water (1 litre daily for 8 weeks)
Study: 8649278
Drug: Intrarectal Quinimax
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal Quinimax 20 mg/kg/12h
Study: 8649278
Drug: Intrarectal Quinimax
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal Quinimax 8 mg/kg/8h
Study: 8649278
Drug: Intrarectal Quinimax
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal Quinimax 13 mg/kg/8h
Study: 8649278
Drug: Intrarectal Quinimax
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal Quinimax 20 mg/kg/8h
Study: 8649278
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine 8 mg/kg/8h
Study: 8649278
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine 12.5 mg/kg in a slow infusion over 4 hours/12h
Study: 8649278
Drug: New rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New rectal quinine formulation 12.8 mg/kg/8h quinine gluconate
Study: 7426887
Drug: Rapid injection
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over ten seconds
Study: 7426887
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over two minutes
Study: 6151828
Drug: Butofilolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butofilolol (200 mg, administered 24 hours and 2 hours before the test)
Study: 24488610
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of Cyclosporin-A (2.5 mg/kg)
Study: 19890345
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with inhaled nitric oxide (20 p.p.m. of iNO)
Study: 18728103
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (75, 100, 150, or 200 microg)
Study: 18728103
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (75, 100, 150, or 200 microg)
Study: 10839333
Drug: Quetiapine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (150 to 600 mg/d)
Study: 10839333
Drug: Quetiapine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (single dose)
Study: 1466184
Drug: 3% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% urea cream (HTH lotion 'light')
Study: 1466184
Drug: 10% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea cream (HTH lotion 'Original')
Study: 24470557
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day) and temsirolimus (50 mg weekly, adjusted based on toxicities)
Study: 24470557
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day) and temsirolimus (maximum tolerated dosage of 15 mg weekly)
Study: 19913323
Drug: Viramidine 600
Normalized name: lidamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viramidine 600 mg twice daily
Study: 19913323
Drug: Ribavirin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1000 or 1200 mg/day based on weight)
Study: 17868354
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic treatment with relief therapy only (Rizatriptan)
Study: 15507508
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (Ca-suppl.) of 850 mg/d
Study: 15507508
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (Ca-suppl.)
Study: 1518261
Drug: Chemotherapy (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (9 different intensive chemotherapy regimens)
Study: 1518261
Drug: Regular maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular maintenance therapy
Study: 1518261
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy or palliative therapy
Study: 27306628
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 20 mg orally every week
Study: 18925348
Drug: Aggression-prevention treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggression-prevention treatment (specific details not provided)
Study: 16897918
Drug: Computer administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer administration of the CTS with increased minimum item display duration
Study: 12837139
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 to 10 mg/day)
Study: 6689091
Drug: 0.1 g
Normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g of dazoxiben
Study: 6689091
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g or 1.0 g of acetylsalicylic acid (ASA)
Study: 25924855
Drug: Crown therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crown therapy (both types)
Study: 23009873
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral ciprofloxacin twice daily for 1 day before and for 2 days after biopsy (group 1)
Study: 23009873
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous amikacin 30 minutes before biopsy plus 500 mg oral ciprofloxacin (group 2)
Study: 17365266
Drug: Conventional cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cream containing 1.15% dithranol, 1.15% salicylic acid and 5.3% coal tar
Study: 11772135
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg plus pseudoephedrine SR 120 mg twice daily for 2 to 3 weeks
Study: 8746927
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate (150 mg/week for two weeks, 300 mg/week for two weeks, and 600 mg/week for two weeks)
Study: 2183732
Drug: Oral clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clindamycin hydrochloride
Study: 11138536
Drug: Oral cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin
Study: 26429571
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D3 supplementation (20,000 IU/week)
Study: 26429571
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on immunomodulatory therapy
Study: 17707091
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy
Study: 23835139
Drug: Group psychoeducation
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychoeducation over six sessions plus treatment as usual (TAU) (n=19)
Study: 23835139
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) alone (n=15)
Study: 17060265
Drug: Sublingual atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual atropine for 48 hours
Study: 17060265
Drug: Sublingual atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual atropine
Study: 14965832
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy given in 8-12 fractions completed in 18-27 days
Study: 14965832
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy in 15-18 fractions within 20-25 days
Study: 11686867
Drug: Soluble recombinant
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble recombinant IL-4 receptor (IL-4 antagonist)
Study: 1406473
Drug: Catheter removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter removal due to end of therapy
Study: 24968000
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg moxidectin
Study: 26645538
Drug: NIRS monitoring
Normalized name: Nirsevimab
DrugBank: Nirsevimab (DB16258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIRS monitoring with treatment guideline intervention
Study: 17963428
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg tablet administered 3 hours before surgery (Group B)
Study: 17963428
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg once daily for 3 days (Group C)
Study: 16225568
Drug: Atosiban (114.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (114.75 mg intravenous infusion) + Labetalol (100 mg orally twice daily)
Study: 16225568
Drug: Atosiban (114.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (114.75 mg intravenous infusion) + Betamethasone (12 mg intramuscular injection)
Study: 16225568
Drug: Atosiban (114.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (114.75 mg intravenous infusion)
Study: 16225568
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 mg orally twice daily)
Study: 16225568
Drug: Betamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (12 mg intramuscular injection)
Study: 12698990
Drug: FMI (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMI (final market image) tablet formulation of oxcarbazepine
Study: 8657506
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation 10 mg/kg/week intravenously
Study: 6994982
Drug: Imipramine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (1 mg/kg for 3 weeks)
Study: 28100342
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of 6 mg nicorandil after guide wire or balloon successfully crossed the target lesion (n=53)
Study: 28100342
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of 300 μg nitroglycerin after guide wire or balloon successfully crossed the target lesion (n=52)
Study: 28100342
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (control group, n=53)
Study: 25880933
Drug: SMT19969 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT19969 (up to 2,000 mg single oral doses)
Study: 25880933
Drug: SMT19969 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT19969 (200 mg BID for 10 days)
Study: 25880933
Drug: SMT19969 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT19969 (single and multiple oral doses)
Study: 25880933
Drug: SMT19969 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT19969 (multiple doses)
Study: 21214361
Drug: Bimatoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost/timolol fixed combination (BTFC) 0.03%/0.5%